---
document_datetime: 2025-03-19 10:55:39
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/fymskina-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: fymskina-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.1771076
conversion_datetime: 2025-12-27 16:26:06.854581
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Fymskina

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0001/G            | This was an application for a group of variations. C.I.6.b - Change(s) to therapeutic indication(s) - Deletion of a therapeutic indication C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure | 15/01/2025                          | 28/01/2025                                  | SmPC, Labelling and PL           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|